Please login to the form below

Not currently logged in

Meda denies takeover report

Swedish pharmaceutical company Meda has denied a media report that Valeant has made a takeover approach for it

Sweden-based Meda has denied reports that Canada-based Valeant Pharmaceuticals International has made a takeover bid for the company.

In a statement Meda said: "Meda's board of directors has not received an approach of the kind that is described in the article. However, there are several collaborations between Meda and Valeant including joint ventures in Canada, Mexico and Australia."

A deal for Meda could be valued at more than $4bn, the Wall Street Journal reported on Tuesday.

Earlier in 2011 Valeant dropped a $5.7bn approach for Cephalon after Israel's Teva Pharmaceutical agreed to buy the US-based pharmaceutical firm for $81.50 a share, beating Valeant's $73-a-share bid.

When contacted by PMLiVE, Valeant said it declined to comment on market speculation.

Valeant recently agreed to acquire Janssen Pharmaceuticals' Ortho Dermatologics and Sanofi's Dermik.

27th July 2011


Featured jobs

Subscribe to our email news alerts


Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

mHealth: The revolution will not be digital
Medical information in precision medicine
Global Medical Information Leader James Oughton reveals the top trends in medical information and precision medicine....
Australian Flu and the dilemma of naming diseases